JP2006512286A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512286A5
JP2006512286A5 JP2004515828A JP2004515828A JP2006512286A5 JP 2006512286 A5 JP2006512286 A5 JP 2006512286A5 JP 2004515828 A JP2004515828 A JP 2004515828A JP 2004515828 A JP2004515828 A JP 2004515828A JP 2006512286 A5 JP2006512286 A5 JP 2006512286A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
polysorbate
viscosity
pharmaceutical
tnf inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004515828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512286A (ja
JP4847011B2 (ja
Filing date
Publication date
Priority claimed from US10/177,566 external-priority patent/US20040002451A1/en
Application filed filed Critical
Publication of JP2006512286A publication Critical patent/JP2006512286A/ja
Publication of JP2006512286A5 publication Critical patent/JP2006512286A5/ja
Application granted granted Critical
Publication of JP4847011B2 publication Critical patent/JP4847011B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004515828A 2002-06-20 2003-06-12 ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法 Expired - Fee Related JP4847011B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/177,566 2002-06-20
US10/177,566 US20040002451A1 (en) 2002-06-20 2002-06-20 Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
PCT/US2003/018995 WO2004000211A2 (en) 2002-06-20 2003-06-12 Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011014985A Division JP2011137005A (ja) 2002-06-20 2011-01-27 ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法

Publications (3)

Publication Number Publication Date
JP2006512286A JP2006512286A (ja) 2006-04-13
JP2006512286A5 true JP2006512286A5 (https=) 2009-07-09
JP4847011B2 JP4847011B2 (ja) 2011-12-28

Family

ID=29734431

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004515828A Expired - Fee Related JP4847011B2 (ja) 2002-06-20 2003-06-12 ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法
JP2011014985A Withdrawn JP2011137005A (ja) 2002-06-20 2011-01-27 ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011014985A Withdrawn JP2011137005A (ja) 2002-06-20 2011-01-27 ペグ化可溶性腫瘍壊死因子受容体の改良組成物とその製造方法

Country Status (8)

Country Link
US (5) US20040002451A1 (https=)
EP (1) EP1578355A4 (https=)
JP (2) JP4847011B2 (https=)
AU (1) AU2003245526B2 (https=)
CA (1) CA2490232C (https=)
MX (1) MXPA04012269A (https=)
PL (1) PL376862A1 (https=)
WO (1) WO2004000211A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US8391959B2 (en) * 2004-09-29 2013-03-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Composition for improving efficiency of drug delivery
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
AU2009309623B9 (en) * 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
US9955802B2 (en) 2015-04-08 2018-05-01 Fasteners For Retail, Inc. Divider with selectively securable track assembly
CN107921072A (zh) * 2015-06-09 2018-04-17 雷柏奥提斯有限公司 微生物群恢复治疗（mrt）组合物和制造方法
CN108697906A (zh) 2015-12-18 2018-10-23 高等教育联邦系统-匹兹堡大学 通过抑制可溶性肿瘤坏死因子的癌症预防和治疗
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
CA1153695A (en) 1979-08-30 1983-09-13 Syoji Ono S-sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5237054A (en) 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (https=) 1994-12-20 1997-08-21 Hoffmann La Roche
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997012244A1 (en) 1995-09-27 1997-04-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining t-cell profiles of immunocompromised subjects
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
JP4516711B2 (ja) 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU3070702A (en) 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
US20040009168A1 (en) 2002-04-05 2004-01-15 Elizabet Kaisheva Multidose antibody formulation
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione

Similar Documents

Publication Publication Date Title
JP2006512286A5 (https=)
JP2005508981A5 (https=)
RU2009149687A (ru) Фармацевтические композиции и способы лечения сухих кератитов
ATE464062T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
DE602005009191D1 (de) Thrombinzusammensetzungen
CA2717605A1 (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
JP2005500309A5 (https=)
RU2008138266A (ru) Составы для парентерального введения лекарств и их применения
ES2224917T1 (es) Composiciones farmaceuticas de agente fibrinolitico.
JP2007500244A5 (https=)
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
WO2008060934A8 (en) Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
EP2292216A3 (en) Stable pharmaceutical composition containing factor VIII
JP2023116498A5 (https=)
RU2004102395A (ru) Жидкая композиция, включающая сложный эфир полиоксиэтиленсорбита и жирной кислоты
CA2528988A1 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
CO5570681A2 (es) Formulaciones de jarabe de ribavirina
AU2002358819A1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
UY27373A1 (es) Formulaciones de interferón beta-humano
JP2006312628A (ja) アシタザノラスト含有水性組成物
DK1653923T3 (da) Oral afleveringssystem omfattende en bivæsket skum
JP5052028B2 (ja) アシタザノラスト含有組成物
MXPA01011842A (es) Composiciones farmaceuticas para la administracion oral de floroglucinol y preparacion de las mismas.
AU714913B2 (en) Intranasal formulations for promoting sleep and method of using the same
GB2426707A (en) A stable parental formulation of levomepromazine and a method for stabilizing said formulation